Loading company…
Valence Discovery developed AI tools for computational drug discovery.
Founded in 2018 and based in Montreal, Canada, Valence Discovery developed AI technologies for drug discovery, including TxPert, which predicts cellular responses to genetic modifications. It served pharmaceutical companies and research institutions. Recursion Pharmaceuticals acquired the company for USD 47.50 million in May 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in